In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bianchi R, Nardelli B, Allegrucci M, Fioretti MC (1985) Efficacia terapeutica del PTT-119 valutata in vivo in modelli sperimentali. G Ital Chemioter 32:1–16
De Barbieri A, Dall'Asta L, Comini A, De Barbieri A, Dall'Asta L, Comini A, Springolo V, Mosconi P, Coppi G, Be-kesi G (1983) Synthesis, acute toxicity and chemotherapeutic anti-cancer activity of a new tripeptidic mustard. Farmacc 38:205–218
Fisher RI, DeVita VT, Hubbard SM (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of Pro-Mace and MOPP chemotherapy. Ann Intern Med 98:304–309
Martoni A, Mazzei T, Mini E, Martoni A, Mazzei T, Mini E, Cellerino R, Periti P, Fioretto L, Pannuti F (1986) Phase I trial of a novel alkylating agent, PTT-119. Cancer Chemother Pharmacol 18: Abstr 192
McKelvey EM, Gottlieb JA, Wilson HE (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in non-Hodgkin's lymphomas. Cancer 38:1484–1493
Portlock CS, Rosenberg SA (1976) Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. Cancer 37:1275–1282
Schein PS, DeVita VT Jr, Hubbard S (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85: 17–22
Yagi MJ, Zanjani M, Holland JF, Bekesi JG (1984) Increased cancericidal activity of PTT-119, a new synthetic bis-(2-chloroethyl)-amino-l-phenylanine derivative with carrier amino acids: 2. In vivo bioassay. Cancer Chemother Pharmacol 12: 77–82
Yagi MJ, Chin SE, Scanlon KJ, Holland JF, Bekesi G (1985) PTT-119, p-F-m-BIS-(2-chloroethyl)-amino-l-Phe-Met-Ethoxy HCl. A new chemotherapeutic agent active against drug-resistant tumor cell lines. Biochem Pharmacol 34:2347–2354
This work was supported by Fondi Ministero Publica Istruzione
About this article
Cite this article
Tura, S., Mazza, P., Gherlinzoni, F. et al. Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemother. Pharmacol. 23, 123–125 (1989). https://doi.org/10.1007/BF00273532
- Cancer Research
- Evaluable Patient